Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5 -- Ignore unavailable to you. Want to Upgrade?

To: GARY P GROBBEL who wrote (99734)	9/15/2010 3:23:08 PM
From: GARY P GROBBEL	Respond to of 120415

INO 1.10....entry into the vaccine sweepstakes at least for malaria... Inovio Pharmaceuticals Awarded Follow-on Funding from the PATH Malaria Vaccine Initiative for DNA Vaccine Development Novel Multi-Antigen Malaria DNA Vaccine Generates Potent Immune Responses in Animal Studies Press Release Source: Inovio Pharmaceuticals, Inc. On Wednesday September 15, 2010, 3:30 am EDT BLUE BELL, Pa.--(BUSINESS WIRE)--Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the PATH Malaria Vaccine Initiative (MVI) has agreed to provide follow-on funding to continue evaluation and development of Inovio’s malaria DNA vaccine candidate in non-human primates. In the prior MVI-funded feasibility study, Inovio’s malaria vaccine candidate induced broad-based immunity to four pre-erythrocytic malaria antigens. In the upcoming non-human primate study, Inovio’s SynCon™DNA vaccine platform, which targets sporozoites and the liver stage of the parasite, is delivered using Inovio’s proprietary electroporation delivery technology. Humoral (antibody) and cellular (T-cell) responses will be assessed in this follow-on program, conducted by the same collaboration of vaccine experts from the University of Pennsylvania School of Medicine and Inovio. Malaria continues to present a major healthcare challenge in the developing world and has been the focus of much attention by global public health agencies. Development of an effective vaccine against Plasmodium falciparum has been a challenge. The parasite undergoes several stages of development during its life cycle and presents different potential target antigens at each stage as it passes through its human and mosquito hosts. Inovio’s vaccine candidate targets the pre-erythrocytic stage of the parasite and focuses on induction of both humoral and cellular responses against multiple target antigens. This approach is intended to help prevent infection of liver cells and to further clear those cells that, despite the antibody response, become infected. By targeting the parasite during the first days after infection, this type of vaccine may prevent the onset of malaria symptoms and further inhibit spread of the disease. Inovio’s technology has previously been shown to induce robust T-cell and antibody responses in different animal models of diseases including influenza, small-pox, HIV, and HPV. Data from the recently completed malaria immunogenicity study will be presented at the Second International Malaria Vaccines for the World Conference in Washington, DC (Sep 28-30). Christian Loucq, MD, Director of the PATH Malaria Vaccine Initiative, stated: “MVI seeks to accelerate the development of malaria vaccines and we are pleased to continue working with Inovio’s novel DNA vaccine platform and its malaria vaccine approach.” Dr. J. Joseph Kim, President and CEO of Inovio, said: "Inovio’s proprietary DNA vaccine technology platform has once again induced strong immune responses for a disease with unmet treatment needs — in this case, malaria. We recently announced best-in-class immunogenicity data from our clinical trial for our HPV/cervical cancer DNA vaccine using the same technology platform. We appreciate MVI’s shared enthusiasm and commitment to advance the application of this next-generation vaccine technology against this challenging disease.” Malaria is caused by parasites that are transmitted to people through the bites of infected mosquitoes. People with malaria often experience fever, chills, and flu-like illness. Left untreated they may develop severe complications and die. Worldwide, about 2.37 billion people in 87 countries are at risk of the disease. According to WHO, in 2008 there were an estimated 247 million cases of malaria and nearly one million deaths – mostly among children living in Africa. A vaccine to prevent malaria infection would complement currently available methods to treat or prevent malaria. On the Internet: PATH Malaria Vaccine Initiative, www.malariavaccine.org PATH, www.path.org About Inovio Pharmaceuticals, Inc. Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. These SynCon™ vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio’s proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio’s clinical programs include HPV/cervical dysplasia and cancer (therapeutic), avian flu (preventive), and HIV vaccines (both preventive and therapeutic). Inovio is developing universal influenza and other vaccines in collaboration with scientists from the University of Pennsylvania. Other partners and collaborators include Merck, National Cancer Institute, HIV Vaccines Trial Network, National Microbiology Laboratory of the Public Health Agency of Canada, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

To: GARY P GROBBEL who wrote (99734)	9/17/2010 10:37:28 AM
From: GARY P GROBBEL	Read Replies (1) \| Respond to of 120415

PSTI...I started writing about it 2 days ago at 1.24...we got as high as 1.75 short time ago...up .45 on heavy heavy vol that came bursting in...quick few bucks. These are the kids of things I am seeing and I am just about ready to call a sentiment change but want to get thru today. Would be first turn around since March when things began to break down in the micros and they were sold heavily rel to damage for April may June but then July and Aug it...2 of the worst months I can ever remember. Then back about 11 trading days ago I sensed a diff tone out here and also a diff in buy/sell activity on my lists and we are still on that horse...if we do ok today then I am wlling to stick my neck out. gpg